"Let's Collaborate for New Drug Development"... K-MEDI Hub and Samjin Pharmaceutical Sign Business Agreement

K-MEDI Hub (Daegu-Gyeongbuk Medical Innovation Foundation, Chairman Yang Jin-young) signed a business agreement with Samjin Pharmaceutical on the 16th to cooperate in new drug development.

The two organizations promised to establish a close cooperative system to discover tangible results, aiming for the advancement of the medical industry through new drug development.

Yang Jin-young, Chairman of K-Medi Hub (third from the left), and Choi Ji-hyun, President of Samjin Pharmaceutical (third from the right), are holding a memorandum of understanding and posing for a commemorative photo.

K-MEDI Hub possesses world-class new drug development infrastructure to support the development of candidate substances, a weak area in the domestic new drug development process, and contributes to the advancement of the domestic medical industry through active exchanges with government ministries and domestic and international institutions.

Samjin Pharmaceutical Co., Ltd. has its own research facilities and maintains comprehensive exchanges with domestic and international institutions to develop innovative new drugs for medical unmet needs such as cancer and fibrotic diseases. Its main products include "Geborin," and it also releases healthcare products.

Through this business agreement, the two organizations plan to promote joint research on new drugs and pharmaceuticals, mutual technical support related to new drug and pharmaceutical research, the establishment of a new drug development network and mutual exchange of research personnel, and other cooperative activities for the development of both organizations.

Yang Jin-young, Chairman of K-MEDI Hub, said, "K-MEDI Hub supports domestic pharmaceutical companies through new drug research and development and pharmaceutical production services," adding, "We will actively support domestic companies and coexist to drive the competitiveness of the national medical industry."